Physician profile
Robert Allen Heavin
NPI 1578675161
$922.50
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $283 · 2021: $22.45.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $302.55 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $140.25 | 2019-2020 | |
| Allergan, INC. | $101.80 | 2019-2020 | |
| Amgen INC. | $62.32 | 2019-2020 | |
| Glaxosmithkline, LLC. | $40.68 | 2019-2020 | |
| Lilly USA, LLC | $36.73 | 2019-2020 | |
| Astellas Pharma US INC | $36.27 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $28.07 | 2019 | |
| Pfizer INC. | $22.96 | 2019 | |
| Abbvie INC. | $22.45 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.23 | 2019 | |
| Janssen Biotech, INC. | $17.78 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.73 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.86 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.96 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $12.27 | 2019 | |
| Medtronic Minimed, INC. | $12.15 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.50 | 2019 | |
| Merck Sharp & Dohme LLC | $10.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Heavin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.